← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Insulin lispro

FDA approved · Rx

Rapid-acting insulin analog

Also known as: Humalog, Admelog, Lyumjev, Humalog Kwikpen, Lyumjev Kwikpen, Lyumjev Tempo Pen, Lyumjev Junior Kwikpen, 28(B)-Lys-29(B)-Pro-Insulin, insuline lispro, Insulina lispro

Evidence score
95/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 368 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 2 cited sources. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Insulin lispro is a modified form of human insulin in which two amino acids near the end of the B chain are swapped, which helps it absorb from under the skin faster than regular human insulin. Like the body's own insulin, it lowers blood sugar by helping cells take up glucose and by reducing glucose release from the liver.

What the evidence shows

Automatic summaryHuman trials

Insulin lispro is FDA-approved for improving blood sugar control in adults and children with diabetes mellitus, sold under brands such as Humalog, Admelog, and Lyumjev. Its effects are well established through hundreds of registered human trials, including Phase 4 studies, and a large published literature.

Key facts

Molecular formula
C257H389N65O77S6
Molecular weight
5814 g/mol
FDA approval
Confirmed on openFDA

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

368registered studies
Phase 4most advanced phase
80completed (sample)
4recruiting (sample)

Glucose Control With Multiple Daily Insulin Injections In Diabetic Patients Hospitalized In A General Medicine Ward

TerminatedNCT00464854

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Phase 3TerminatedNCT00700622

Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors

CompletedNCT02155023

A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes

CompletedNCT04484779

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

905papers referencing Insulin lispro

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

Diabetes2000

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

Diabetes2000

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.

Lancet Diabetes Endocrinol2018

Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes.

Physiol Meas2004

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.